dc.contributor.author
Lohkamp, Laura-Nanna
dc.contributor.author
Schinz, Maren
dc.contributor.author
Gehlhaar, Claire
dc.contributor.author
Guse, Katrin
dc.contributor.author
Thomale, Ulrich-Wilhelm
dc.contributor.author
Vajkoczy, Peter
dc.contributor.author
Heppner, Frank L.
dc.contributor.author
Koch, Arend
dc.date.accessioned
2018-06-08T04:10:11Z
dc.date.available
2016-07-12T09:50:49.123Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/16706
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-20887
dc.description.abstract
Giant Cell Glioblastoma (gcGBM) and Pleomorphic Xanthoastrocytoma (PXA) are
rare astroglial tumors of the central nervous system. Although they share
certain histomorphological and immunohistochemical features, they are
characterized by different clinical behavior and prognosis. Nevertheless, few
cases remain uncertain, as their histomorphological hallmarks and
immunophenotypes do correspond to the typical pattern neither of gcGBM nor
PXA. Therefore, in addition to the routinely used diagnostic histochemical and
immunohistochemical markers like Gömöri, p53 and CD34, we analyzed if genetic
variations like MGMT promoter methylation, mutations in the IDH1/2 genes, or
BRAF mutations, which are actually used as diagnostic, prognostic and
predictive molecular markers in anaplastic glial tumors, could be helpful in
the differential diagnostic of both tumor entities. We analyzed 34 gcGBM and
20 PXA for genetic variations in the above-named genes and found distinct
distributions between both groups. MGMT promoter hypermethylation was observed
in 3 out of 20 PXA compared to 14 out of 34 gcGBM (15% vs. 41.2%, p-value
0.09). BRAF V600E mutations were detected in 50% of the PXA but not in any of
the gcGBM (50% vs. 0%, p-value < 0.001). IDH1 R132 and IDH R172 mutations were
not present in any of the PXA and gcGBM cases. Our data indicate, that in
addition to the histological and immunohistochemical evaluation, investigation
of MGMT promoter methylation and in particular BRAF V600E mutations represent
reliable additional tools to sustain differentiation of gcGBM from PXA on a
molecular basis. Based on these data specific BRAF kinase inhibitors could
represent a promising agent in the therapy of PXA and their use should be
emphasized.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to
Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
PLoS ONE. - 11 (2016), 6, Artikel Nr. e0156422
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0156422
dcterms.bibliographicCitation.url
http://dx.doi.org/10.1371/journal.pone.0156422
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000024983
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000006757
dcterms.accessRights.openaire
open access